← Bangkok Dusit Medical Services overview

Bangkok Dusit Medical Services vs Universal Health Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲3▼1

BDMS Q3 rebound: revenue up, profit record forecast, risks remain

  • Revenue rebound and occupancy recovery After a weak Q2, July revenue jumped 8% and occupancy rebounded to 65%, with August revenue up 10%. Analysts called Q2 the year's low and maintained Buy ratings.

    This is the key new positive development that drove the stock in Q3.

  • Record Q3 profit forecast and higher targets Brokers forecast a record Q3 profit of 4.5–4.6 billion baht and raised price targets to as high as 25 baht, citing medical tourism and an 18.8% September rebound in Middle East revenue.

    This shows analyst optimism and upward revisions that likely supported the stock price.

  • WellEra wellness project adds long-term growth The WellEra wellness project is expected to contribute to long-term growth, expanding BDMS's service offerings and tapping into the growing wellness tourism market.

    This is a new strategic initiative that could drive future growth and investor interest.

  • Bangkok floods threaten Q3 profit Bangkok floods could cut Q3 profit by 0.5–1.5%, posing a risk to the strong recovery and potentially dampening investor sentiment.

    This is a key risk factor that could negatively impact Q3 results and stock performance.

September 2026
▲3▼1

BDMS Q3 profit set to hit record on strong August revenue

  • Record Q3 profit forecast Brokers expect BDMS to report a record quarterly profit of 4.5–4.6 billion baht for Q3 2026, up sharply from Q2, as August revenue growth reached 10%, the first double-digit gain since 2024.

    This is the central new development driving positive sentiment for the period.

  • Broker upgrades and higher targets Multiple brokerages raised their price targets for BDMS, with some going up to 25 baht, and maintained buy ratings, citing the weak baht, medical tourism, and a recovering Middle East patient segment.

    Analyst upgrades directly influence investor expectations and stock price.

  • Middle East patient recovery Middle Eastern patient revenue rose 18.8% in September, signaling a rebound from earlier weakness caused by regional unrest, which had previously dragged down international income.

    This shows a key international segment is recovering, supporting future growth.

  • Flood risk to Q3 profit Bangkok floods could reduce Q3 profit by 0.5–1.5%, posing a short-term risk to earnings, though the impact is expected to be limited.

    This is a new risk factor that could dampen the positive outlook.

Latest
▲4

BDMS Set for Record Q3 Profit as Brokers Turn Bullish

  • Record Q3 profit expected Bualuang Securities expects BDMS to report a record Q3 2026 core profit of 4.6 billion baht, up 7% year-on-year and 42% quarter-on-quarter, driven by flu and COVID season, recovering foreign patients, and a low base from weak Cambodia business. This directly boosts earnings expectations and supports the share price.

    This is the most direct and material new catalyst for BDMS's earnings outlook.

  • Brokers raise targets and recommend buying Multiple brokerages issued buy ratings and target prices for BDMS this period: KKPS at 23.50 baht, Asia Plus at 25.00 baht, LHSEC at 25.00 baht, and Bualuang at 23.00 baht. These recommendations reflect growing confidence and can attract investors, pushing the price up.

    Broker upgrades and buy calls are a key driver of investor sentiment and demand for the stock.

  • Middle East patient recovery Middle Eastern tourist numbers rose 18.8% year-on-year in September, with complex cases returning. BDMS derives about 4% of revenue from this group, but higher-margin cases support profit recovery. This helps offset earlier weakness from Middle East unrest.

    The recovery in foreign patients is a significant revenue and margin driver for BDMS.

  • Flood impact limited, demand rebound expected Brokerages estimate the Bangkok floods will have a minimal impact on BDMS, with only 0.5-1.5% of Q3 profit affected. Postponed checkups are expected to return in October, supporting Q4 revenue. This reassures investors that the flood is not a major threat.

    It removes a potential negative overhang and points to a near-term rebound.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

Universal Health Services Inc (UHS)

Q3 2026
▲2▼2

UHS: AI Edge and Talkspace Deal Offset by Labor Costs and Guidance Cut

  • AI Coding Platform Margin Edge UHS's AI coding platform generates about $50 million annually, which could give it a lasting cost advantage over nonprofit hospital rivals and support profit margins.

    This new technology-driven advantage is a key positive force for UHS's profitability and stock.

  • Talkspace Acquisition to Boost EPS The $835 million purchase of Talkspace adds 6,000 therapists and is expected to increase earnings per share, expanding UHS's behavioral health services.

    This major acquisition is a new growth driver that could lift UHS's earnings and stock price.

  • Nursing Shortage Raises Labor Costs The nursing shortage worsened from 28% to 39%, driving up labor expenses. Operating costs rose 9%, pressuring margins despite revenue growth.

    This escalating cost issue directly threatens UHS's profitability and is a major negative force.

  • Guidance Cut After Q2 Miss UHS lowered its full-year EPS and EBITDA guidance after missing second-quarter estimates, signaling weaker-than-expected financial performance and future uncertainty.

    The guidance cut is a clear negative signal that likely weighed on investor sentiment and the stock price.

August 2026
▲2▼1

UHS earnings miss and guidance cut, offset by Talkspace deal and buyback

  • Q2 earnings miss and lowered full-year guidance UHS missed second-quarter EPS estimates and cut its full-year adjusted earnings guidance to $22.28-$23.65 from a prior range. The company was the only healthcare firm to miss EPS that week. Lower profit expectations weigh on the stock because investors pay less for each dollar of future earnings.

    This is the main negative force this period, directly explaining the initial sharp stock drop.

  • Talkspace acquisition completed, expected to boost EPS UHS closed its $835 million all-cash purchase of virtual therapy provider Talkspace, adding 6,000 licensed therapists and access to over 200 million people through health plans and employers. Management expects the deal to slightly increase adjusted EPS within a year, expanding UHS's behavioral health reach.

    This is a new, concrete growth move that supports the stock by expanding UHS's digital behavioral health business.

  • Buyback completed and stock seen as undervalued UHS finished its long-running share repurchase program, and the stock trades well below a widely followed fair-value estimate of $205.24. Fewer shares outstanding can lift earnings per share, and the discount may attract value-focused investors. Risks remain from Medicaid policy changes and workforce shortages.

    This explains a positive capital-return and valuation angle that supports the stock despite the earnings miss.

  • Revenue beat and raised revenue guidance, but profit outlook cut UHS beat second-quarter revenue estimates and raised its full-year revenue guidance, yet lowered its EBITDA and EPS forecasts. The stock has gained 5.7% since the report, but analyst profit estimates have fallen over the past month. Revenue growth is solid, but margins are under pressure.

    This captures the mixed picture: top-line strength versus bottom-line caution, which is the core tension for the stock now.

Latest
▲2▼1

UHS earnings miss and guidance cut, offset by Talkspace deal and buyback

  • Q2 earnings miss and lowered full-year guidance UHS missed second-quarter EPS estimates and cut its full-year adjusted earnings guidance to $22.28-$23.65 from a prior range. The company was the only healthcare firm to miss EPS that week. Lower profit expectations weigh on the stock because investors pay less for each dollar of future earnings.

    This is the main negative force this period, directly explaining the initial sharp stock drop.

  • Talkspace acquisition completed, expected to boost EPS UHS closed its $835 million all-cash purchase of virtual therapy provider Talkspace, adding 6,000 licensed therapists and access to over 200 million people through health plans and employers. Management expects the deal to slightly increase adjusted EPS within a year, expanding UHS's behavioral health reach.

    This is a new, concrete growth move that supports the stock by expanding UHS's digital behavioral health business.

  • Buyback completed and stock seen as undervalued UHS finished its long-running share repurchase program, and the stock trades well below a widely followed fair-value estimate of $205.24. Fewer shares outstanding can lift earnings per share, and the discount may attract value-focused investors. Risks remain from Medicaid policy changes and workforce shortages.

    This explains a positive capital-return and valuation angle that supports the stock despite the earnings miss.

  • Revenue beat and raised revenue guidance, but profit outlook cut UHS beat second-quarter revenue estimates and raised its full-year revenue guidance, yet lowered its EBITDA and EPS forecasts. The stock has gained 5.7% since the report, but analyst profit estimates have fallen over the past month. Revenue growth is solid, but margins are under pressure.

    This captures the mixed picture: top-line strength versus bottom-line caution, which is the core tension for the stock now.

July 2026
▲1▼1

UHS swings on AI upside, labor shortages, and mixed earnings

  • AI coding platform adds $50M annualized revenue UBS says hospitals may gain more from AI than insurers, noting UHS already earns about $50 million a year from an AI coding platform. This supports profit margins and gives UHS a multiyear edge over slower nonprofit rivals, pushing the stock up.

    Shows a new, concrete technology-driven revenue and margin driver for UHS.

  • Nursing shortage worsens, raising labor costs The nursing shortage rate jumped from 28% to 39%, and peer HCA cut its profit outlook. For UHS, this means higher wages and tighter margins, a real headwind that pushed shares down 5.6% on the day and keeps pressure on the stock.

    Identifies a key supply-side cost pressure that directly hurts UHS profitability.

  • Q2 profit rises but guidance cut on higher costs UHS reported higher Q2 net income of $358.4 million and 8.3% revenue growth, but then cut full-year EPS guidance and missed Q2 expectations as operating expenses rose 9%. The strong quarter is offset by cost worries, leaving the stock down on the guidance cut.

    Captures the latest earnings result and the guidance cut that moved the stock.

▲1▼1

UHS swings on AI upside, labor shortages, and mixed earnings

  • AI coding platform adds $50M annualized revenue UBS says hospitals may gain more from AI than insurers, noting UHS already earns about $50 million a year from an AI coding platform. This supports profit margins and gives UHS a multiyear edge over slower nonprofit rivals, pushing the stock up.

    Shows a new, concrete technology-driven revenue and margin driver for UHS.

  • Nursing shortage worsens, raising labor costs The nursing shortage rate jumped from 28% to 39%, and peer HCA cut its profit outlook. For UHS, this means higher wages and tighter margins, a real headwind that pushed shares down 5.6% on the day and keeps pressure on the stock.

    Identifies a key supply-side cost pressure that directly hurts UHS profitability.

  • Q2 profit rises but guidance cut on higher costs UHS reported higher Q2 net income of $358.4 million and 8.3% revenue growth, but then cut full-year EPS guidance and missed Q2 expectations as operating expenses rose 9%. The strong quarter is offset by cost worries, leaving the stock down on the guidance cut.

    Captures the latest earnings result and the guidance cut that moved the stock.